Primary mediastinal large B-cell lymphoma: Difference between revisions
No edit summary |
|||
| Line 107: | Line 107: | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center | ||
|+ '''Treatment of primary mediastinal large B-cell lymphoma<ref name= canadiancancer> | |+ '''Treatment of primary mediastinal large B-cell lymphoma<ref name= canadiancancer>Primary mediastinal large B-cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/primary-mediastinal-large-b-cell-lymphoma/?region=nb. Accessed on March 7, 2016 </ref> | ||
! style="background: #4479BA; color:#FFF;" | Therapy | ! style="background: #4479BA; color:#FFF;" | Therapy | ||
! style="background: #4479BA; color:#FFF;" | Description | ! style="background: #4479BA; color:#FFF;" | Description | ||
| Line 114: | Line 114: | ||
| style="padding: 5px 5px; background: #DCDCDC;" | [[Chemotherapy]] | | style="padding: 5px 5px; background: #DCDCDC;" | [[Chemotherapy]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* A commonly used combination chemotherapy is CHOP: [[Cyclophosphamide]], [[Doxorubicin]], [[Vincristine]], {{and}} [[Prednisone]] | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | [[Biological therapy]] | | style="padding: 5px 5px; background: #DCDCDC;" | [[Biological therapy]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Rituximab]] may be added to chemotherapy. | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | [[Radiation therapy]] | | style="padding: 5px 5px; background: #DCDCDC;" | [[Radiation therapy]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[External beam radiation therapy]] to the mass in the chest may be used after chemotherapy. | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | [[Stem cell transplant]] | | style="padding: 5px 5px; background: #DCDCDC;" | [[Stem cell transplant]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* A [[stem cell transplant]] may be offered to some people if their lymphoma returns or relapses after treatment. | |||
|} | |} | ||
Revision as of 15:14, 7 March 2016
For patient information, click Insert page name here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Synonyms and keywords::
Overview
Pathophysiology
Associated Conditions
Microscopic Pathology
On microscopic histopathological analysis, are characteristic findings of primary mediastinal large B-cell lymphoma.
Causes
There are no established causes for primary mediastinal large B-cell lymphoma.
Differentiating type page name here from other Diseases
Primary mediastinal large B-cell lymphoma must be differentiated from other diseases such as:
Epidemiology and Demographics
Age
The incidence of primary mediastinal large B-cell lymphoma increases with age; the median age at diagnosis is 35 years.
Gender
Females are more commonly affected with primary mediastinal large B-cell lymphoma than males.
Risk Factors
There are no established risk factors for primary mediastinal large B-cell lymphoma.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for primary mediastinal large B-cell lymphoma.
Natural History, Complications and Prognosis
Diagnosis
Staging
Staging for primary mediastinal large B-cell lymphoma is provided in the following table:[1]
| Stage | Involvement | Extranodal (E) status |
|---|---|---|
| Limited | ||
| Stage I | One node or a group of adjacent nodes | Single extranodal lesions without nodal involvement |
| Stage II | Two or more nodal groups on the same side of the diaphragm | Stage I or II by nodal extent with limited contiguous extranodal involvement |
| Stage II bulky | II as above with "bulky" disease | Not applicable |
| Advanced | ||
| Stage III | Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement | Not applicable |
| Stage IV | Additional noncontiguous extralymphatic involvement | Not applicable |
Symptoms
Symptoms of the primary mediastinal large B-cell lymphoma include:
- Fever
- Weight loss
- Night sweats
- Skin rash
- Painless swelling in the neck, axilla, groin, thorax, and abdomen
Physical Examination
Vitals
- Fever is often present
HEENT
Thorax
- Thoracic masses suggestive of central lymphadenopathy
- Localized anterosuperior mediastinal mass
Abdomen
- Abdominal masses suggestive of central lymphadenopathy
Extremities
Laboratory Findings
Laboratory tests for primary mediastinal large B-cell lymphoma include:
- Complete blood count (CBC)
- Blood chemistry studies
- Cytogenetic analysis
- Flow cytometry
- Immunohistochemistry
- Immunophenotyping:
Biopsy
Lymph node or bone marrow biopsy is diagnostic of .
CT
CT scan may be helpful in the diagnosis of primary mediastinal large B-cell lymphoma.
MRI
MRI scan may be helpful in the diagnosis of primary mediastinal large B-cell lymphoma.
Other Imaging Findings
PET scan may be helpful in the diagnosis of primary mediastinal large B-cell lymphoma.
Treatment
Medical Therapy
| Therapy | Description |
|---|---|
| Chemotherapy |
|
| Biological therapy |
|
| Radiation therapy |
|
| Stem cell transplant |
|
References
- ↑ Cheson, Bruce D.; Fisher, Richard I.; Barrington, Sally F.; Cavalli, Franco; Schwartz, Lawrence H.; Zucca, Emanuele; Lister, T. Andrew; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute (2014-09-20). "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 32 (27): 3059–3068. doi:10.1200/JCO.2013.54.8800. ISSN 1527-7755. PMID 25113753.
- ↑ Primary mediastinal large B-cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/primary-mediastinal-large-b-cell-lymphoma/?region=nb. Accessed on March 7, 2016